4-Star Stocks Poised to Pop: Solazyme

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, renewable oil producer Solazyme (NAS: SZYM) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Solazyme's business and see what CAPS investors are saying about the stock right now.

Solazyme facts

Headquarters (founded)San Francisco (2003)
Market Cap$592.6 million
IndustryConsumable fuels
Trailing-12-Month Revenue$44.8 million
ManagementCo-Founder/CEO Jonathan Wolfson
Co-Founder/Chief Technology Officer Harrison Dillon
Trailing-12-Month Return on Equity(41.8%)
Cash/Debt$218.7 million / $20.25 million
CompetitorsFuelCell Energy
ExxonMobil
Valeant Pharmaceuticals

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 95% of the 294 members who have rated Solazyme believe the stock will outperform the S&P 500 going forward.  

A couple of months ago, one of those Fools, SamsaricSufferer, helped bring the opportunity to our community's attention:

[Solazyme] continues to devote tremendous resources to R&D as it seeks to expand its potential markets far beyond biofuels. They have spent money to protect that R&D through patents. These patents have been wide ranging, extending its potential into medical, nutritional, agricultural markets. As many know, building up a portfolio of [intellectual property] grants one a substantial moat against competition. ... Speculative? Of course. Foolish? Only in the best sense of this site.

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Solazyme may not be your top choice.

If that's the case, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now. 

Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.

At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Solazyme. Motley Fool newsletter services have recommended buying shares of Exxon. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners